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1. Introduction 
With the increase in human life expectancy many health concerns start to be important, 
which raises the need for more and different therapeutic solutions. 
One of the emerging issues that attracted the attention of research teams looking for new 
and better medicines is prevention of hormonal dependent tumors in both genders and the 
relief of climacteric symptoms in post-menopausal women, as the prevention of 
cardiovascular diseases (CVD). 
For both of the above situations testosterone, estrona and estradiol metabolism are 
fundamental for a possible cardiovascular effect or a desoxinucleic acid (DNA) damage in 
breast cancer. Phytoestrogens, as isoflavones, in a first approach, seems to be potentially 
useful solutions. These compounds have the ability to mimic estrogens and induce an 
estrogen-like effect dependent on their affinity for alpha and beta estrogen receptors (ERs) 
[1], and this is related to their chemical structures.  
Phytoestrogens were discovered by Bennetts et al, who were trying to identify the cause of a 
specific sheep breeding problem in Western Australia. They implicated equol, a metabolite 
of daidzin that is an isoflavone existing in subterranean clover pastures [2]. Four decades 
later, in 1984, this compound was identified in human Urine by Setchell et al [3] and related 
to consumption of soy and further implicated in a possible prevention of hormonal 
dependent tumors, cardiovascular diseases and osteoporosis.  
At that time, the world was focused on the French Paradox (data collected with French 
population) that claimed the ingestion of antioxidants, mainly from red wine as the alcohol 
itself, could be a panacea for cancer prevention and cardiovascular diseases. According to 
data from the world's largest study of heart disease, conducted by the World Health 
Organization (WHO), during the past decade in 21 countries with 10 million men and 
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women, French heart disease statistics appeared to have been under-estimated and the 
"French Paradox" overestimated. The French rate of heart disease was actually similar to that 
of the Italians, Spanish, and the Germans (mainly southern Germany), but still lower than 
many other countries. 
Despite that, other researchers looking in a different way for the same reasons made 
epidemiological studies on Asian populations in the '90s that revealed a possible 
relationship between the ingestion of soy and the prevention of hormonal dependent 
tumors and also a lower incidence of climacteric symptoms in postmenopausal women. 
These results, known as the "Japanese Paradox" (data collected with Japonese  population), 
induced Western people to consume soy and soy derivatives rich in isoflavones as genistein, 
daidzein, glycitein and the respective glucosidic forms (genistin, daidzin and glycitin). A 
large number of studies have attempted to demonstrate that soy consumption decreases the 
risk of developing several chronic diseases, in particular, cancer, osteoporosis [4, 5], 
cardiovascular diseases [6], and also the relief of climacteric symptoms [7]. Up until now 
however, the majority of these benefits have not been proven [for review see 9]. 
These two epidemiologic studies are mainly focus on prevention of cardiovascular diseases 
and cancer, using phenolic compounds as the targets for this bioactivity. The first one, 
French paradox, fail and leave behind an important side effect, cirrhosis, in people that 
increase the intake of wine all over this last decades. Related to the "Japanese Paradox", the 
scientific community starts to have data enough to think that this concept needs to be 
evaluated with caution to prevent a future failure. 
Until now, in Europe isoflavones are considered as food compounds, nevertheless they are 
antinutrient compounds, and is the European Food Safety Authority (EFSA) that is 
responsible for the risk assessment evaluation of them. They recognize the potential 
importance for human health of the issue of isoflavones from food digestion, but should the 
alleged beneficial or detrimental health effects be scientifically proven. The Isoflavones 
ESCO working group evaluates the relevant scientific information available. This includes 
inter alia: to assess the potential of isolated isoflavones to trigger adverse human health 
effects; the possible human health benefits of the use of isolated isoflavones for the general 
population and particularly for women with complaints during and after the menopausal 
period; whether there is any scientific basis for differences concerning the hazard 
assessment of isolated isoflavones from soy and/or red clover in comparison with soy or red 
clover extracts. The final document will be public and available at EFSA web site soon 
(http://www.efsa.europa.eu/en/esco/escoisoflavones.htm). 
For this reason in the present chapter we’ll not focus an overview of the isoflavones, as that 
is the current work of, but we’ll discuss other points of view that can contribute for 
understanding of the topic especially for cancer and relief of climacteric symptoms. In this 
last point, recently (2010) Rebbeck et al [12] presented a study were they evaluated whether 
genes involved in the metabolism of steroid hormones are associated with hormone levels 
or menopausal symptoms. They used a population-based prospective sample of 436 African 
American (AA) and European American (EA) women who were premenopausal at 
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enrollment and were followed longitudinally through menopause. Evaluation of the 
relationship between steroid hormone metabolism genotypes at catechol O-
methyltransferase (COMT), cytochrome P450 (CYP) as the isoformes CYP1A2, CYP1B1, 
CYP3A4 and CYP19, Sulfotransferase 1A1 (SULT1A1), and SULT1E1 with hormone levels 
and menopausal features were carried out. The results show in EA women, SULT1E1 
variant carriers had lower levels of dehydroepiandrosterone sulfate, and SULT1A1 variant 
carriers had lower levels of estradiol, dehydroepiandrosterone sulfate, and testosterone 
compared with women who did not carry these variant alleles. In AA women, CYP1B1*3 
genotypes were associated with hot flashes (odds ratio [OR], 0.62; 95% CI, 0.40-0.95). 
Interactions of CYP1A2 genotypes were associated with hot flashes across menopausal stage 
(P = 0.006). Interactions of CYP1B1*3 (P = 0.02) and CYP1B1*4 (P = 0.03) with menopausal 
stage were associated with depressive symptoms. In EA women, SULT1A1*3 was associated 
with depressive symptoms (OR, 0.53; 95% CI, 0.41-0.68) and hot flashes (OR, 2.08; 95% CI, 
1.64-2.63). There were significant interactions between SULT1A1*3 and hot flashes (P < 
0.001) and between SULT1A1*2 and depressive symptoms (P = 0.007) on menopausal stage, 
and there were race-specific effects of SULT1A1*2, SULT1A1*3, CYP1B1*3, and CYP3A4*1B 
on menopause. These results suggest that genotypes are associated with the occurrence of 
menopause-related symptoms or the timing of the menopausal transition [10].  
Isoflavones as we’ll explain later in this chapter will interfere with most of these enzymes 
and Caucasians and Asians present polymorphic changes, in some of them, that can change 
the bioactive response to various situations, from compounds metabolism to cancer 
induction or prevention. 
2. Chemistry, main food sources, bioactivity and possible toxicity of 
isoflavones related to ethnic differences 
Isoflavones are biologically active heterocyclic phenolic compounds (subgroup of  
isoflavonoids) (Figure 1) that are absorbed by the intestine, circulate systemically, and are 
eliminated by the kidneys and liver [11]. In plants isoflavones occur predominantly as  β-
glucosides (genistin, daidzin, glycitin), or as acetyl-β-glucosides and malonyl-β-glucosides [12, 
13]. Genistein is the more abundant isoflavone in the majority of soy products and also the 
most active of these compounds, and being able to interact with the estrogenic receptors [14]. 
Traditionally the main food sources of isoflavones are soy and other beans and pulses, and 
also fermented soy foods, where the glucosides have been transformed into aglycones which 
are absorbed more efficiently than glucosides. 
In the past these have been more commonly consumed by Asian populations, but are 
growing in popularity in Europe. Similarly, in recent decades a new generation of soy 
products have entered the market (e.g. yogurts, cheeses, soy milk drinks, infant formula’s) 
and commonly consumed food products incorporating soy flour (e.g. bakery products) and 
protein isolates (e.g. meat products and soy meatless products such as soy burgers). More 
recently, the development of nutritional supplements rich in isoflavones has targeted niche 
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markets in response to scientific research, that is still controversial, but that suggests a 
beneficial effect from these food components. 
Isoflavones were first discovered in the 1930’s, as a bioactive agent, following the disruption 
of estrogen action and increased infertility in sheep that had been grazing on red clover, 
thereby earning the often used name ‘phytoestrogens’. Subsequently isoflavones have been 
shown to bind to, or indirectly interact with several key nuclear receptors, including 
hormonal (estrogen receptors alpha and beta [ERs], progesterone and androgen receptors), 
xenobiotic sensing receptors (Pregnane X receptors [PXR] and Peroxisome proliferator 
activated receptors [PPARs], and steroidogenic and hypothalamus-pituitary-thyroid (HPT) 
axis pathways. Isoflavones are structurally similar to the endogenous estrogen 17-beta 
estradiol, but much less potent on binding to the ERs, although genistein, the more active 
isoflavone, have a greater binding affinity for ER beta (43.9% related to 100% for estradiol 
[15]). 
These compounds, as other phytoestrogens, are molecules with the ability to mimic estrogen 
pharmacological action through the linkage with ERs, and because of that are called 
estrogen-like molecules [15].  
The benefits and the inherent risks associated to the ingestion of estrogen-like molecules are 
related to their binding affinity to beta-ERs and to alpha-ERs. 
 
Figure 1. Chemical structures of iso-flavone equivalents 
Beta-ERs are mainly located in bones, brain, thymus, bladder, and the cardiovascular 
system. Its activation by estrogenic compounds or estrogen-like compounds can probably 
improve or prevent conditions such as osteoporosis and cardiovascular diseases [16, 17]. In 
the other hand, alpha-ERs appear to predominate in breast, uterus and ovary; some authors 
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report that linkage between estrogen or estrogen-like molecules and alpha-ERs is potentially 
dangerous. In breast cancer, for example, it could promote proliferation of damaged DNA 
[18,19]; and it can also lead to endometrial hyperplasia, as concluded in a randomized, 
double-blind, placebo-controlled study evaluating the safety of a long-term treatment (up to 
5 years) with soy isoflavones. Although no cases of malignancy were detected, the 
hyperplasia called into question the long-term safety of phytoestrogens with regard to the 
endometrium [8]. 
Another important  issue indicates a possible relationship between low doses of isoflavones 
and an increase in tumor proliferation, as it was pointed out by some authors.The same 
authors also concluded that, genistein and daidzein could not only stimulate pre-existing 
tumors, but also antagonize the effects of the tamoxifen (antitumour agent). Thus, women 
with breast cancer or with a history of a previous breast cancer event should be made aware 
of the risks of potential tumor proliferation while taking soy products [20]. Previously, 
Hsieh et al, also pointed out the possibility that lower amounts of genistein could stimulate 
alpha – receptors and influence the proliferation of breast cancer cells [22]. 
It is furthermore of particular relevance the fact that genistein can be estrogenic and 
antiestrogenic in human body. Clarify these mechanisms, as it was done for tamoxifen, can 
be crucial to the understanding of a possible benefit/risk ratio. For example, although 
tamoxifen has been useful both in treating breast cancer patients and in decreasing the risk 
of getting breast cancer in women at high risk, it also has some serious side effects. These 
side effects arise from the fact that while tamoxifen acts as an antiestrogen that blocks the 
effects of estrogen on breast cells, it mimics the actions of estrogen in other tissues such as 
the uterus. Its estrogen-like effects on the uterus stimulate proliferation of the uterine 
endometrium and increase the risk of uterine cancer [23]. The same was refered before in the 
data from, Unfer et al, (2004) [8]. 
The relevance of ethnic metabolism will be crucial to clarify some misunderstandings. As an 
example of the ethnic importance of polymorphic enzymes in metabolic pathways a meta-
analysis conducted combining the data with 34 published studies that included 11 962 
cancer cases and 14 673 controls in diverse cancers was carried out. The SULT1A1*2 
revealed contrasting risk association for UADT cancers (OR=1.62, 95% CI: 1.12, 2.34) and 
genitourinary cancers (OR=0.73, 95% CI: 0.58, 0.92). Furthermore, although SULT1A1*2 
conferred significant increased risk of breast cancer to Asian women (OR=1.91, 95% CI: 1.08, 
3.40), it did not confer increased risk to Caucasian women (OR=0.92, 95% CI: 0.71, 1.18). 
Thus risk for different cancers in distinct ethnic groups could be modulated by interaction 
between genetic variants and different endogenous and exogenous carcinogens [24]. 
Even all these results were carried out with Europeans (which don´t consume soy very 
often) and others with Asians ( which included this food many years ago in their normal 
diet plan), it isn’t frequent  to discuss their metabolic pathways.  
As it is known, populations vary genetically and differ in the occurrence and frequency of 
particular genetic polymorphism depends on the time when the mutation occurred in 
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relation to human migrations. If it occurred after the populations split, it will be unique to 
one population and its descendants. If it happened in the ancestor population, it is possible 
present in all descendent groups. A well-known example is the frequent ALDH2 deficiency 
in Asian individuals which is rarely found in Caucasians. As metabolizing enzymes are 
involved in the detoxification on endogenous and xenobiotic toxins, in the activation of 
procarcinogens, in the formation of reactive intermediates and in their neutralization, many 
studies have been undertaken concerning the correlation between genetic polymorphisms 
and metabolizing enzymes and cancer risk [25].  
Ethnic differences in metabolism are a consequence of various factors as, for example, 
adaptation to different environments, differences in nutrition, behavior and cultural 
differences. This genetic polymorphism of metabolizing enzymes cause differences in effects 
and toxicity of the ingested compounds between individuals and all population. The so called 
“idiosyncratic drug interactions” are now explained on the basis of genetic polymorphisms. 
Beside the genetic variability differences can appear after enzyme induction or inhibition by 
the affected compound itself or by others or xenobiotics, e.g., from foods [25]. 
In Phase I  metabolization, genistein, daidzein and equol (important metabolite of daidzein-
7-O-glucoside) inhibit the Cytochrome P450 (CYP) 1A2, 1B2, 2E1, 3A4 and in phase II they 
induce UDP glucuronosyl transferase (UGT), Glutathione-S-Transferase (GST) and Quinone 
Redutase (QR); SULT1A1, SULT1A3  and SULT1E1 are inhibited for all of them [26]. 
CYP 1A2, for example, is important for estrogen metabolization (E1 and 2) in 2- or 4-OH E1 
and 2 followed of the 4-OH E1 and 2 sulphate metabolite by SULT1A1*2 and *3, or to 2- and 
4-OCH3 E1 and 2 by COMT. The inhibition of CYP 1A2 and SULT1A1, SULT1A3, probably 
can induce E1 and E2 to be metabolized by CYP 3A4 (*1B) to 16-alpha OH E1 and 2.  
Rebbeck et al, also observed race-specific associations with CYP1B1, CYP1A2, and SULT1A1 
on menopausal symptoms; race-specific effects of SULT1A1*2, SULT1A1*3, CYP1B1*3, and 
CYP3A4*1B on time to late premenopause, early menopausal transition, and menopause; 
and interactions of race with SULT1A1*2 and SULT1A1*3 on time to menopause [10].  
The involvement of all these enzymes in the different ethnic groups constitutes a gap in the 
understanding of what can be used with benefit from other continents. The controversy 
persists regarding the role of a low ratio of 2-hydroxyestrone /16alpha-hydroxyestrone (2-
OHE1)/(16 -OHE1) as a potential estrogen metabolism marker of increased risk for breast 
cancer [27]. Was suggested that soy consumption increases this ratio only in women who are 
equol producers given a possible protection against breast cancer [28].  
The European American women that carry the CYP3A4*1B  allele important in these last 
steps of metabolization of estrogens were indicated for a early menopause independent of 
the SULT1A1*2 or *3 type. The SULT1A1*2 (Arg213His) have a frequency of ca 30% for 
Caucasians and African Americans but only 8-17% for Asians [25].  
GST present important genetic differences and is induce by isoflavones. The consequences 
of polymorphic GST isoenzymes are probably more relevant for carcinogenesis and for the 
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detoxication of toxic xenobiotics and of chemotherapeutics than for drug metabolism in 
general. For example, 44-64% of the Asians present a GSTT1*0 polymorphism against 10-
36% in Caucasians with the consequent difference in the metabolizing behavior [25].  
This is also important for possible interactions between those molecules and some 
medicines, special in polimedicated patients. Daidzein, one of the principal isoflavones in 
soybean, can inhibit CYP1A2 activity and alter the pharmacokinetics of theophylline in 
healthy volunteers. Theophylline is a bronchodilator with a narrow therapeutic index (5–20 
mg/L), and it is primarily eliminated by hepatic metabolism mediated by CYP1A2. [26].  
Steroid hormone metabolism genes are not generally responsible for interindividual 
variation in steroid hormone levels or with changes in these levels across the menopausal 
transition. However a better understanding of all these mechanisms will be important to 
prevent future damage if we ingest compounds that will change the natural equilibrium of 
ethnic groups. 
If these associations are confirmed, they may provide information about the prediction of 
menopausal symptoms and allow clinicians to individualize and target hormone therapy in 
women experiencing menopausal symptoms. Because hormone exposures, genotypes 
involved in hormone metabolism, and the phenotypic manifestations of these factors on 
symptoms are all associated epidemiologically with risk of cancer and other diseases, a 
better understanding of the role of genotypes and intermediate phenotypes such as 
hormone levels may ultimately assist our understanding of steroid hormone– related 
disease etiology and prevention [10]. 
So although, until now, the risk assessment for soy products is not clear enough to consider 
their consumption safe, humans are increasingly being exposed to isoflavones in soy and 
soy derivatives (other products containing isoflavones from different sources aren’t so rich). 
Thus better information about the safety of these soy phytoestrogens is urgently needed.  
3. Examples of products available to be consumed by European 
population 
In this section is provided an overview (not exhaustive but presenting some discuss points) 
of the potential benefit/risk impact of nutritional products and supplements, that include 
isoflavones in their composition and that are recommended mainly for climacteric relief 
symptoms in post-menopausal women and/or prostatic cancer prevention in man and CVD 
prevention.  
The European Prospective Investigation into Cancer and Nutrition (EPIC) study evaluated 
in 2002 the consumption of soy products in 10 European countries [29]. Results from this 
study revealed that soy consumption at that time was low in Western Europe and that non-
dairy substitutes were the most frequently consumed items.  
In this section we’ll demonstrate the wide variation of isoflavone levels that these products 
may provide to the consumer. Because there are not recommendations of the optimal 
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isoflavone consumption, the information displayed in these products should be clearly 
specified, especially in the case of health supplements. This is essential for accurate risk 
assessment studies, where knowing the exposure level of the population to these products 
and more specifically the exposition to each isoflavone is fundamental. 
Nowadays, over the counter (OTC) tablet preparations [30, 31], nutraceuticals and various 
supplements with isoflavones extracted from soy [32] and other plants are sold in various 
countries. These products are often used by postmenopausal women to do hormonal 
therapy replacement as another option to allopathic medicines with oestrogen derivatives, 
and also with the claim of cancer prevention. However, the impact of that exposure in 
Caucasian women health is underestimated. 
As a result of the promising scientific findings related to isoflavones, the soy-processing 
industry has grown worldwide from manufacturing alternative dairy products and milk-
free infant formulas to provide a wider range of products embracing all types of tastes and 
consumer health concerns. These new products, sometimes named as second generation soy 
foods, are based in the inclusion of soy ingredients (soy pieces, soy powder, soy flour, soy 
protein, etc) among the ingredient list of food items commonly consumed by western 
populations. 
Development of new soy products is especially important in Europe where the population 
does not accept the characteristic soybean flavor. Some years ago, only a few traditional soy 
foods were common items in European markets, and among those, soy nuts, soy sauce, tofu 
and soymilk were easily found, but the recent appearance of the so-called second-generation 
of soy foods; products made by adding soy ingredients (soy protein) to a wide variety of 
manufactured foods resulting in products which generally simulate familiar dishes [32]. 
A number of soy protein-based products are included, mainly meat substitutes (texturised 
soy protein) in a number of forms, as well as dairy-products substitutes. Same protein is 
added to enrich a number of foods commonly present in European diets: bread, cookies and 
soups or dietary supplements (powders) and energy bars used to complement sport diets. 
The latest version to use soy protein or isoflavone isolates appeared in the form of capsules 
or tablets directed, and labelled, to promote the claimed health benefits of soy isoflavones 
between the consumers [32]. 
It is well known that isoflavone levels in soy-based products depend primarily upon the 
soybean variety used. Isoflavone content within a single variety can differ three times from 
year to year [33]. In some studies, this variability has been attributed to climatic and 
environmental factors [34]. Moreover, soybean processing and storage conditions usually 
lead to a significant isoflavone loss in soy-based products [35]. In addition, isoflavone 
glucoside conjugates are easily alterable during extraction and cooking[36], and it has been 
even shown variations between products included in the same batch [32]. 
In some cases the presence of isoflavones is intended and therefore its concentration is 
known, but in the majority of the soy foods the levels of isoflavones need to be quantified in 
order to evaluate the possible health effect of these products.  
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Results from our previous work with some of the above cited products, selected soy-foods 
produced and distributed within Europe (Table 1), provide total isoflavone values for a 
possible evaluation of the potential exposure to these molecules [32].  
 
 
Table 1. Groups of soy based foods and health supplements 
In this work a total of 115 soy-based products were purchased at local retailers and natural 
health food stores in Finland, Spain, UK and Portugal during the years 2002-2005. 
Commercial availability and European manufacture were the only selection criteria. The 
selected items belong to different groups of soy foods and a classification was needed in 
order to allow the comparison between levels of isoflavones provided by the different 
products. Items were divided into four different groups: 1) Traditional soy foods, 2) Non-
dairy soy products, 3) Meat analogues, 4) Second-generation soy foods and 5) Health 
supplements. Food samples were (when necessary) freeze-dried, homogenized and stored at 
-70 °C until analysis [32].  
Soy isoflavones in samples were quantified as previously reported [30, 38, 39] using a HPLC 
systems equipped with a Coularray detector or diode array detection. Peaks corresponding 
to soy isoflavones were confirmed by LC/MS-MS as previously reported [39]. Synthetic 
standards were used for quantification through calibration curves, and control samples, 
were introduced between run to assure repeatability was acceptable (CV <15%) over the 
analysis time. All reagents were from major suppliers and HLPC-grade. Results are mean 
values of triplicate analyses, and were only accepted when coefficient of variation (CV) 
between the replicates was <15%. Only values above the limits of quantification of the 
method for each isoflavone (1 ppm, depending on the analyte) are reported [39]. All values 
are expressed as aglycone equivalents. 
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Figure 2. Isoflavone means in Traditional soy foods, no-dairy soy products and meat analogues 
analised as examples of European consume. 
In Figure 2, from our previous data [32], genistein was found to be the most prevalent 
isoflavone in Traditional soy foods, no-dairy soy products and meat analogues. In second 
generation soy foods, daidzein was the most prevalent isoflavones. However differences 
between the various products were considerable. 
Diverse studies have been conducted in different countries in order to analyze the 
isoflavone content in soy products. Chan et al determined the concentrations and 
distribution of isoflavones in 47 soy-based foods [40]. They also studied the conjugation 
pattern of isoflavones and found that varied within and between food groups as influenced 
by the types of soybeans and the processing or cooking techniques used. The authors found 
very high values in certain foods and concluded that might not be safe, supporting the 
relevance of the risk assessment for the recommendation of safe intake levels. Similar results 
were obtained by Boniglia et al [41].  
Three years ago, Boniglia et al, achieved similar results. These authors presented a study of 
the isoflavone content of 14 soy-based Italian dietary supplements – indicated for the 
improvement of perimenopausal and menopausal symptoms. The objective was to quantify 
soy isoflavones fraction after hydrolysis into free aglycones. They noticed that, in the 
examined products, the amounts of isoflavones were frequently expressed ambiguously. 
None of the products stated whether the isoflavone content of the product was expressed as 
aglycones or as conjugates. Even worse, each product revealed a different aglycone 
concentration profile. They also concluded that this difference was probably related to the 
different sources of raw materials and methods used in the processing and preparation of 
extracts. They also observed that in more than half the supplements tested, the actual values 
contained were below those stated and below those expected to relief perimenopausal and 
menopausal symptoms [41]. 
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Similarly, our study of a 59 selected soy health supplements shown a large variation in the 
composition, and a wide difference between the content of isoflavones analyzed and that 
reported in the product [32]. 
Our study demonstrates, as the others cited before, the wide variation of isoflavone levels 
that these products may provide to the consumer. Because there are not recommendations 
of the optimal isoflavone consumption, the information displayed in these products should 
be clearly specified, especially in the case of health supplements. This is essential for 
accurate risk assessment studies, where knowing the exposure level of the population to 
these products and more specifically the exposition to each isoflavone is fundamental. 
Despite the predominant isoflavone forms in soybeans [38] and non-fermented soy products 
(like soy protein or soy milk derivates) are glucosides [42]; fermented soy foods (like soy 
sauce) contain mainly aglycones [43]. The form in which isoflavones are present in soy-
based foods and health supplements is important to assess the bioavailability of these 
products [36], Considering that genistein is, in a theoretical point of view [15,44], about 1000 
times more active that daidzein the heath benefit and/or the toxicity could be different in 
two apparently identical products.  
For this confusing data our previous proposition was, and still is, applying the calculation of 
“Theoretical Efficacy (of isoflavones) Related to Estradiol (TERE) [44]. Like that it is possible 
evaluate the theoretical impact of exposure to estrogen-like activity of isoflavones in various 
countries from all the data of different studies already published [44]. This theoretical 
calculation estimates the “Theoretical Efficacy (TE)” of a mixture with different bioactive 
compounds in a way to obtain a “Theoretical Efficacy Related to Estradiol (TERE)”. The 
theoretical calculation that was proposed for some of the authors of this chapter integrates 
different knowledge about this subject and sets methodological boundaries that can be used 
to analyse data already published. The outcome should set some consensus for new clinical 
trials using isoflavones (isolated or included in mixtures) that will be evaluated to assess 
their therapeutically activity.  
To do the theoretical calculation [44] the amounts of isoflavones were multiply for the “ERs 
binding affinities” based on the values obtained in literature [15]. After applying the 
proposed model, "Theoretical efficiency related to estradiol (TERE), for each mixture of 
isoflavones, the" Theoretical Efficiency (TE) was estimated which can be used to compare 
the potential bioactivity [44]. 
Daidzein and genistein do not have the same binding affinity to alpha- and/or beta-ERs [15]. 
Also known and frequently mentioned by several authors is that the linkage of oestrogens 
or oestrogenic compounds to alpha-ERs could be dangerous with breast cancers because it 
could aid the proliferation of damaged DNA in tumours [45, 46]. The amounts theoretical 
linked from the different isoflavones to the alpha- oestrogen receptors as an add benefit 
(when added to the beta-receptors affinity) but also as a potential risk to be under 
evaluation. 
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However, it is also accepted that beta-ERs are mainly located in bones, brain, thymus, 
bladder, cardiovascular system and its activation by estrogenic compounds, or compounds 
with the ability to mimic estrogenic molecules, such as phytoestrogens, can improve and 
prevent conditions like osteoporosis and cardiovascular diseases [17, 47] and this will be 
used as the benefit parameter. 
In global terms the total efficacy of the TERE will be determined adding these two values. 
However the amount linked to the alpha-receptors will be consider as a possible risk 
limitation, which that needs to be evaluated when the increased dose will induce an 
improved TERE but the risk assessment for the toxicity can be a handicap. Ultimately, 
different extracts could be compared, even when the relative amounts present in the extracts 
are very different. 
The example of TERE calculation for samples show in Figure 2 is presented in Table 2, using 
“Second generation soy foods” data. 
 
 
Second generation soy 
foods 
Receptor Type 
 
Intake 
(mg/100g) 
Alpha-ERs Beta-ERs 
daidzein 29,2 
(29.2 x 0.031/100) 
0.009 
(29.2 x 0.020/100) 
0.006 
genistein 22,09 
(22.09 x 0.86/100) 
0.19 
(25 x 43.9/100) 
9.7 
Total 51.79 0.199 9.706 
TE 9.9 (= 0.199 + 9.706) 
TERE 
(100 total linkage to ERs/9.9 TE)  = 1/10.1 of the theoretical activity of the 
estradiol 
RISK ~ 2%  
BENEFIT   ~ 98% 
Daidzein binding affinity for alpha–ER is 0.031 and 0.020 for beta-ER [15]; 
Genistein binding affinity for alpha–ER is 0.86 and 43.9 for beta-ER [15]. 
Table 2. Example of TERE calculation with mean values for Second generation soy foods using the 
“Estrogen Receptor affinity binding values” with daidzein and genistein. 
From the total values in Figure 3 and 4 is possible evaluate the amount of daidzein and 
genistein linked to both receptors and have an idea about the Theoretical Efficacy (TE) of 
these components if related to estradiol (TERE), Figure 5. 
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Figure 3. “Estrogen Receptor affinity binding values” for daidzein and genistein content in samples of 
Group I to IV. 
 
 
 
Figure 4. TE values for samples of Group I to IV. 
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With the exception of Non-dairy soy products that present very low bioactivity related to 
estradiol the other three groups have values between 7 and almost 14% of the estradiol 
bioactivity. 
Nevertheless the apparent majority of benefice related to risk, as was pointed out above, the 
low amounts of isoflavones linked to alpha receptors can increase the possibility of 
proliferation in hormonal dependent tumours and the safe amounts were not evaluated yet. 
If the same analysis is made with health supplements the values are absolutely different. In 
Figure 6 it is shown the TE for the highest values of daidzein and genistein found in our 
samples (daidzein 371.48 and genistein 172,47 mg/g of pill) [32]. The pill with the content of 
172,47mg of genistein also had 208.41mg of daidzein. The TE for this product is almost 80% 
of the bioactivity of estradiol with a clear uncertainty of influence in the bioability of these 
compounds in human body. 
The exposure risk of all those products is unknown and needs to be evaluated in a near 
future even no enough data for now make sense.  
The data presented herein intend to demonstrate the wide range of isoflavone levels that 
different products may provide to the consumer, even when recommended for the same 
therapeutic effect and still if the product keeps the same isoflavones profile all the time. Its 
relevant to mention that the majority of the soy suppliers breed a wide range of soy 
cultivars, which results in a different mixture of compounds, and consequently in a variable 
final product composition and hazard [19, 38]. 
The Europeans, as can be seen in results presented recently by Konar et al, in 2012 
consumed legumes with low levels of dietary isoflavones. In this study, 6 legumes 
(chickpea, red kidney bean, haricot bean, yellow lentil, red lentil and green lentil) were 
analysed to determine their contents for 10 different isoflavones (both free and 
conjugated). Methanolic extracts obtained by ultrasound-assisted extraction were 
analysed by triple quadrupole LC-MS/MS. Chickpeas were the best source of isoflavones 
(3078 372 mu g/kg total content), with a significant amount of biochanin A and its 
conjugated form, sissotrin. Kidney beans had the second highest concentration of 
isoflavones (1076 mu g/kg) and were particularly rich in genistin (946.4 +/- 228.5 mu g/kg). 
The total isoflavone concentrations of yellow split lentils, green lentils, red lentils and 
haricot beans were each below 200.0 mu g/kg. However it was determined that the 
legumes commonly consumed in Western diets (those analyzed in this study) are not so 
concentrated as soy and soy products as sources of Isoflavones [48]. 
As it was explained and discussed in the previous section the metabolic pathways and the 
genetic polymorphic enzymes involved in detoxication of the ingested compounds in our 
body can conduce to a different bioactivities and consequent risk impact in the various 
ethnic groups. Only a full risk assessment will prevent the danger or will help to understand 
the benefit of an increase in the isoflavone intake by Caucasians that for the moment is 
absolutely out of control. 
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Figure 5. TERE values for samples of Group I to IV. 
 
Figure 6. TE values for samples of Group V (only for highest daidzein and genistein content). 
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4. Conclusions 
The above findings emphasize the need for a thorough correct risk assessment to be carried 
out to evaluate the differences between the various isoflavones, their relative levels in 
formulations (dietetic supplements, foods soy based, etc) and their safety profile, in order to 
establish limits for safe therapeutic effects. Various interactions with conventional medicines 
have already been published and it is important to alert already medicated patients who are 
also consuming soy or soy based products. The relationship between this intake and cancer 
and or cardiovascular diseases prevention is unclear moreover the danger of a cancer 
improvement. 
Without such a risk assessment ad libitum consumption of these compounds could be 
hazardous.  
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